UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 188

Sortiert nach

Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas

British journal of haematology, 2024-01, Vol.204 (1), p.151-159

2024

Volltextzugriff (PDF)

Integration of transcriptional and mutational data simplifies the stratification of peripheral T‐cell lymphoma

American journal of hematology, 2019-06, Vol.94 (6), p.628-634

2019

Volltextzugriff (PDF)

Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology

Scientific reports, 2021-12, Vol.11 (1), p.23823-23823, Article 23823

2021

Volltextzugriff (PDF)

Utility of flow cytometry ascitic fluid analysis for rapid diagnosis of B-cell peritoneal lymphomatosis

Mediterranean journal of hematology and infectious diseases, 2022-09, Vol.14 (1), p.e2022068-e2022068

2022

Volltextzugriff (PDF)

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

The Lancet (British edition), 2019-12, Vol.394 (10216), p.2271-2281

2019

Volltextzugriff (PDF)

Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations

Hematological oncology, 2023-02, Vol.41 (1), p.3-15

2023

Volltextzugriff (PDF)

Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment

Cancers, 2022-03, Vol.14 (7), p.1742

2022

Volltextzugriff (PDF)

Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics

British journal of haematology, 2022-07, Vol.198 (1), p.82-92

2022

Volltextzugriff (PDF)

Secondary primary malignancies after CD‐19 directed CAR ‐T‐cell therapy in lymphomas: A report from the Italian CART ‐ SIE study

British journal of haematology, 2024-06

2024

Volltextzugriff (PDF)

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Journal of clinical oncology, 2016-07, Vol.34 (21), p.2484-2492

2016

Volltextzugriff (PDF)

Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

The oncologist (Dayton, Ohio), 2019-08, Vol.24 (8), p.e720-e729

2019

Volltextzugriff (PDF)

Prognostic impact of TP53 mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trial

British journal of haematology, 2022-03, Vol.196 (5), p.1184-1193

2022

Volltextzugriff (PDF)

MACOP-B and Involved-Field Radiotherapy Is an Effective and Safe Therapy for Primary Mediastinal Large B Cell Lymphoma

International journal of radiation oncology, biology, physics, 2008-11, Vol.72 (4), p.1154-1160

2008

Volltextzugriff (PDF)

Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia

Cancers, 2023-04, Vol.15 (9), p.2411

2023

Volltextzugriff (PDF)

Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma

British journal of haematology, 2019-09, Vol.186 (6), p.e217-e219

2019

Volltextzugriff (PDF)

Impact of anti‐SARS‐CoV‐2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study

Hematological oncology, 2023-08, Vol.41 (3), p.343-353

2023

Volltextzugriff (PDF)

Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma

Leukemia & lymphoma, 2020-07, Vol.61 (9), p.2122-2128

2020

Volltextzugriff (PDF)

Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination

Blood, 2012-10, Vol.120 (16), p.3222-3228

2012

Volltextzugriff (PDF)

Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS

Frontiers in oncology, 2023-06, Vol.13, p.1171031

2023

Volltextzugriff (PDF)

1 – 25 von 188

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(167)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(121)
Life Sciences & Biomedicine
(117)
Humans
(80)
Hematology
(61)
Male
(49)
Female
(46)
Oncology
(40)
Middle Aged
(35)
Adult
(33)
Aged
(27)
Lymphoma
(27)
Prognosis
(24)
Treatment Outcome
(22)
Patients
(21)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(17)
Adolescent
(16)
Young Adult
(15)
Prospective Studies
(14)
Follow-Up Studies
(13)
Cardiac & Cardiovascular Systems
(12)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas

Biological features and outcome of diffuse large B‐cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective ‘Elderly Project’ by the Fondazione Italiana Linfomi

Integration of transcriptional and mutational data simplifies the stratification of peripheral T‐cell lymphoma

Electronic case report forms generation from pathology reports by ARGO, automatic record generator for onco-hematology

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

Utility of flow cytometry ascitic fluid analysis for rapid diagnosis of B-cell peritoneal lymphomatosis

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Management of patients with lymphoma and COVID‐19: Narrative review and evidence‐based practical recommendations

KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study

Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial

Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment

Chemotherapy after PD‐1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics

Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

Secondary primary malignancies after CD‐19 directed CAR ‐T‐cell therapy in lymphomas: A report from the Italian CART ‐ SIE study

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

Time to progression of mantle cell lymphoma after high‐dose cytarabine‐based regimens defines patients risk for death

Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

Prognostic impact of TP53 mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trial

MACOP-B and Involved-Field Radiotherapy Is an Effective and Safe Therapy for Primary Mediastinal Large B Cell Lymphoma

Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia

Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma

Impact of anti‐SARS‐CoV‐2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study

Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma

Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination

Case Report: Severe cutaneous adverse event associated with checkpoint inhibition in the setting of CAR T-cell therapy: beyond CRS

Suchergebnisse filtern